Bide Pharmatech (688073.SH) achieved a net profit of 1.23 billion yuan in 2024, representing a growth of 12.07%.

Bide Pharmatech (688073.SH) disclosed its performance report for the year 2024, with the company achieving operating income of 1.102 billion yuan, a year-on-year increase of 0.93%; net profit attributable to owners of the parent company was 1.23 billion yuan, an increase of 12.07%; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 1.09 billion yuan, a decrease of 11.20%. Basic earnings per share were 1.38 yuan. During the reporting period, the company deepened its internationalization strategy, accelerated its overseas market layout, continued to expand overseas business income; meanwhile, it reduced costs and increased efficiency internally, promoted digitalization upgrades and process optimization, comprehensively improved management efficiency, and achieved steady revenue growth, with profitability indicators such as gross profit margin and profit margin continuously increasing.